Records containing: Hormone Refractory Prostate Cancer
This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.
Follow recorded terms in Drug Alerts for Android. Free includes unlimited local condition follows and an on-open recent-record watchlist. Plus adds no ads and personal organization tools.
All
FDA submission records
EMA medicine records
ClinicalTrials.gov record updates
ClinicalTrials.gov records with results posted
-
CLINICAL_TRIALS study record update · 2026-02-04The BARCODE 2 Study - The Use of Genetic Profiling to Guide Prostate Cancer Treatment
-
CLINICAL_TRIALS study record update · 2023-05-25A PhaseI/II Study Evaluating the Safety, Tolerability, and Maximally Tolerated Dose of L-377202 Administered Once Every 3 Weeks
-
CLINICAL_TRIALS study record update · 2023-04-28Phase II Study of Adenovirus/PSA Vaccine in Men With Hormone - Refractory Prostate Cancer
-
CLINICAL_TRIALS study record update · 2023-04-19A Double Blind, Dose Response Phase II, Multicentre Study of Radium 223 (Alpharadin®) for the Palliation of Painful Bone Metastases in Hormone Refractory Prostate Cancer Patients
-
CLINICAL_TRIALS study record update · 2021-02-18A Phase II Study of TKI258 in Patients With Castration-resistant Prostate Cancer
- Organize your saved records without ads with Plus.
-
CLINICAL_TRIALS study record update · 2020-12-19A Phase IA/IB, Two Arm, Multi-center, Open-label, Dose Escalation Study of Oral LBH589 Alone and in Combination With IV Docetaxel and Oral Prednisone in Hormone Refractory Prostate Cancer (HRPC)
-
CLINICAL_TRIALS study record update · 2020-10-19A Randomized Phase II Study to Assess the Activity of TroVax® (MVA-5T4) Plus Docetaxel Versus Docetaxel Alone in Subjects With Progressive Hormone Refractory Prostate Cancer
-
CLINICAL_TRIALS study record update · 2020-05-13A Phase I/II, Open-Label, Dose-Escalation and -Expansion, Safety, Pharmacokinetics and Efficacy Study of SHR3680 in Patients With Metastatic Castration-Resistant Prostate Cancer
-
CLINICAL_TRIALS study record update · 2019-11-22A Phase I/II Trial of ABI-008 (Nab-docetaxel) in Patients With Hormone-refractory Prostate Cancer
-
CLINICAL_TRIALS study record update · 2019-10-03A PHASE 1, OPEN-LABEL, DOSE-ESCALATION SAFETY AND PHARMACOKINETIC STUDY OF MDV3100 IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER
-
CLINICAL_TRIALS study record update · 2019-03-06A Dose-escalation Phase I Trial of PD-1 Knockout Engineered T Cells for the Treatment of Castration Resistant Prostate Cancer
-
CLINICAL_TRIALS study record update · 2017-08-14Chemotherapy Response Monitoring With 18F-choline PET/CT in Hormone Refractory Prostate Cancer
-
CLINICAL_TRIALS study record update · 2017-07-02Phase II Study of Weekly Cabazitaxel for Advanced Prostate Cancer in "Unfit" Hormone-Refractory Patients Previously Treated With Docetaxel
-
CLINICAL_TRIALS study record update · 2017-06-12A Randomized, Open-label, Phase 2 Trial of Sipuleucel-T With Concurrent Versus Sequential Administration of Abiraterone Acetate Plus Prednisone in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
-
CLINICAL_TRIALS study record update · 2016-10-12A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study Evaluating the Pain Palliation Benefit of Adding Custirsen to a Taxane for Second-Line Chemotherapy in Men With Castrate Resistance Prostate Cancer
-
CLINICAL_TRIALS study record update · 2015-04-06A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase 3 Study of Denosumab on Prolonging Bone Metastasis-Free Survival in Men With Hormone Refractory Prostate Cancer
-
CLINICAL_TRIALS study record update · 2014-08-05Exploratory Study of Molecular Phenotype Changes and Personalized Treatment for Patients With Castration Resistant Prostate Cancer
-
CLINICAL_TRIALS study record update · 2014-05-07A Double-blind, Randomised, Multiple Dose, Phase III, Multicentre Study of Alpharadin in the Treatment of Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases
-
CLINICAL_TRIALS study record update · 2013-12-05A Phase 2 Randomized Study of Cediranib (AZD2171) Alone Compared With the Combination of Cediranib (AZD2171) Plus BMS-354825 (Dasatinib, Sprycel) in Docetaxel Resistant, Castration Resistant Prostate Cancer
-
CLINICAL_TRIALS study record update · 2013-02-07A Single Arm, Two Center, Phase II Study of RAD001 in Patients With Metastatic, Hormone-Refractory Prostate Cancer
-
CLINICAL_TRIALS study record update · 2012-08-07A Multi-National Phase III Study of Satraplatin Plus Prednisone or Placebo Plus Prednisone in Patients With Hormone Refractory Prostate Cancer Previously Treated With One Cytotoxic Chemotherapy Regimen
-
CLINICAL_TRIALS study record update · 2012-05-11A Phase II Trial of Docetaxel/Prednisone in Combination With Sargramostim as Treatment for Hormone-refractory Prostate Cancer
-
CLINICAL_TRIALS study record update · 2012-05-04Salvage Radiotherapy vs Observation for Castration Resistant Prostate Cancer in Central China
-
CLINICAL_TRIALS study record update · 2012-03-30Phase I/IIa Study of RNActive®-Derived Therapeutic Vaccine in Advanced or Metastatic Hormone Refractory Prostate Cancer
-
CLINICAL_TRIALS study record update · 2012-03-12Open Label, Randomized Multicentric Phase II Clinical Trial of Mycobacterium w in Combination With Docetaxel Versus Docetaxel in Metastatic Hormone Refractory Prostate Cancer.